SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001636282-24-000010
Filing Date
2024-03-01
Accepted
2024-03-01 06:14:57
Documents
18
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A syre-20231231.htm   iXBRL 10-K/A 154377
2 EX-31.1 ex311_spyre-202312311.htm EX-31.1 4020
3 EX-31.2 ex312_spyre-202312311.htm EX-31.2 3939
  Complete submission text file 0001636282-24-000010.txt   401312

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT syre-20231231.xsd EX-101.SCH 2835
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT syre-20231231_lab.xml EX-101.LAB 41977
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT syre-20231231_pre.xml EX-101.PRE 24550
19 EXTRACTED XBRL INSTANCE DOCUMENT syre-20231231_htm.xml XML 5615
Mailing Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453 6176515940
Spyre Therapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-37722 | Film No.: 24706756
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)